Suzhou Lanxite Biotechnology Co., Ltd.

Main study objectives To study the pharmacokinetics of the test preparation sulindac tablets (specification: 0.2g, produced by Chengdu Tongde Pharmaceutical Co., Ltd., provided by Suzhou Langke Biotechnology Co., Ltd.) and the reference preparation sulindac tablets (Sulindac®, specification: 200mg; produced by Watson Pharma Private Ltd., licensed by WATSON LABORATORIES INC) in humans after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fasting and fed state. Secondary study objectives To evaluate the safety of the test preparation sulindac tablets and the reference preparation sulindac tablets (Sulindac®) after a single oral administration in fasting and fed state in healthy Chinese subjects.

The progesterone soft capsules of Suzhou Langke Biotechnology Co., Ltd. were used as the test preparation, and the progesterone soft capsules of Besins Healthcare Benelux were used as the reference preparation to evaluate the relative bioavailability and bioequivalence in humans.

Primary objective: To study the pharmacokinetics of the test preparation Dydrogesterone Tablets (Specification: 10 mg, Suzhou Langke Biotechnology Co., Ltd.) and the reference preparation Dydrogesterone Tablets (trade name: Daphaston®, specification: 10 mg, Abbott Healthcare Products B.V.) in healthy Chinese female subjects after a single oral administration in fasting and fed state, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test preparation (T) Dydrogesterone Tablets and the reference preparation (R) Dydrogesterone Tablets (Daphaston®) in healthy Chinese female subjects after a single oral administration in fasting and fed state.